These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37449060)

  • 1. Antibody production and tolerance to the α-gal epitope as models for understanding and preventing the immune response to incompatible ABO carbohydrate antigens and for α-gal therapies.
    Galili U
    Front Mol Biosci; 2023; 10():1209974. PubMed ID: 37449060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
    Galili U
    Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse-heart grafts expressing an incompatible carbohydrate antigen. II. Transition from accommodation to tolerance.
    Ogawa H; Mohiuddin MM; Yin DP; Shen J; Chong AS; Galili U
    Transplantation; 2004 Feb; 77(3):366-73. PubMed ID: 14966409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens.
    Galili U
    Transplantation; 2004 Oct; 78(8):1093-8. PubMed ID: 15502700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-gal A/B, a novel anti-blood group antibody identified in recipients of abo-incompatible kidney allografts.
    Galili U; Ishida H; Tanabe K; Toma H
    Transplantation; 2002 Dec; 74(11):1574-80. PubMed ID: 12490791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene.
    Ogawa H; Yin DP; Galili U
    Gene Ther; 2004 Feb; 11(3):292-301. PubMed ID: 14737089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen.
    Mohiuddin MM; Ogawa H; Yin DP; Shen J; Galili U
    Transplantation; 2003 Feb; 75(3):258-62. PubMed ID: 12589143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen, II: tolerance induction on memory B cells.
    Mohiuddin MM; Ogawa H; Yin DP; Galili U
    Blood; 2003 Jul; 102(1):229-36. PubMed ID: 12649147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen.
    Ogawa H; Yin DP; Shen J; Galili U
    Blood; 2003 Mar; 101(6):2318-20. PubMed ID: 12406874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation.
    Tanemura M; Yin D; Chong AS; Galili U
    J Clin Invest; 2000 Feb; 105(3):301-10. PubMed ID: 10675356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Liver Sinusoidal Endothelial Cells in Induction of Carbohydrate Reactive B Cells Tolerance Through the Programmed Death 1/Programmed Death Ligand 1 Pathway.
    Igarashi Y; Onoe T; Ohdan H
    Transplantation; 2015 Nov; 99(11):2325-36. PubMed ID: 26247556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies.
    Galili U
    Front Mol Biosci; 2021; 8():746883. PubMed ID: 34805272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of anti-Gal B cells by alpha-Gal ricin1.
    Tanemura M; Ogawa H; Yin DP; Chen ZC; DiSesa VJ; Galili U
    Transplantation; 2002 Jun; 73(12):1859-68. PubMed ID: 12131678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α1,3Galactosyltransferase knockout pigs produce the natural anti-Gal antibody and simulate the evolutionary appearance of this antibody in primates.
    Galili U
    Xenotransplantation; 2013; 20(5):267-76. PubMed ID: 23968556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.
    Galili U
    Immunol Cell Biol; 2005 Dec; 83(6):674-86. PubMed ID: 16266320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies.
    Galili U; Buehler J; Shohet SB; Macher BA
    J Exp Med; 1987 Mar; 165(3):693-704. PubMed ID: 2434599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase.
    LaTemple DC; Galili U
    Xenotransplantation; 1998 Aug; 5(3):191-6. PubMed ID: 9741457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
    Galili U
    Vaccine; 2020 Sep; 38(42):6487-6499. PubMed ID: 32907757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.
    Galili U
    Immunology; 2013 Sep; 140(1):1-11. PubMed ID: 23578170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.